Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06326814 · ClinicalTrials.gov registry record · Phase 1
A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults
A Phase 1 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT06326814 is a Phase 1 study that has completed, run by Sanofi. The registered enrollment target is 54 participants.
The verdict
NCT06326814, a Phase 1 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
Primary objective * The tolerability and safety of SAR443809 Secondary * The PK parameters of SAR443809 * The PD activity of SAR443809 * The immunogenicity of SAR443809
Interventions
- DRUG Placebo
- DRUG Humanized anti-Factor Bb monoclonal antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2021-10-11 |
| Est. Completion | 2023-05-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06326814
The ClinicalTrials.gov registry entry for NCT06326814 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06326814 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06326814 about?
NCT06326814 is a clinical study titled "A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults". Primary objective * The tolerability and safety of SAR443809 Secondary * The PK parameters of SAR443809 * The PD activity of SAR443809 * The immunogenicity of SAR443809
What is the current status of trial NCT06326814?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2021-10-11. Estimated completion is 2023-05-05.
What interventions are being tested in trial NCT06326814?
The interventions under investigation include: Placebo (DRUG), Humanized anti-Factor Bb monoclonal antibody (DRUG).
Who is sponsoring clinical trial NCT06326814?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.